Praxis Precision Medicines
56 articles about Praxis Precision Medicines
-
Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting
4/12/2024
Praxis Precision Medicines, Inc. today announced that it will deliver presentations of two abstracts showcasing progress of its clinical program evaluating ulixacaltamide for adults with essential tremor (ET) at the American Academy of Neurology (AAN) 2024 Annual Meeting taking place in Denver, Colorado, April 13 – 18, 2024.
-
Praxis Precision Medicines to Participate in Upcoming April Conferences
4/5/2024
Praxis Precision Medicines, Inc. today announced that management will take part in upcoming conferences in April.
-
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 02, 2024
4/2/2024
Praxis Precision Medicines, Inc. announced that on April 1, 2024, the Compensation Committee of Praxis’ Board of Directors granted non-qualified stock option awards to purchase 300 shares of its common stock and restricted stock unit awards covering 225 shares of its common stock to one new non-executive employee under the Praxis Precision Medicines, Inc. 2024 Inducement Plan.
-
Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering - March 28, 2024
3/28/2024
Praxis Precision Medicines, Inc. announced the pricing of its underwritten public offering of 3,318,585 shares of its common stock at a public offering price per share of $56.50 and, in lieu of shares of common stock, pre-funded warrants to purchase up to an aggregate of 221,238 shares of common stock at a purchase price of $56.4999 per pre-funded warrant, which equals the public offering price per share of the common stock less the $0.0001 per share exercise price of each pre-funded warrant.
-
Praxis Precision Medicines, Inc. Announces Proposed Public Offering - March 27, 2024
3/27/2024
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance, announced a proposed public offering of its common stock and, in lieu of common stock to certain investors, prefunded warrants to purchase shares of common stock.
-
Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients
3/26/2024
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance, provided an update on its Phase 2a proof of concept study evaluating PRAX-628 in epilepsy patients with PPR.
-
Praxis Precision Medicines to Host PRAX-628 Program Update
3/25/2024
Praxis Precision Medicines, Inc. announced that it will host a virtual program update to discuss its PRAX-628 program in epilepsy on Tuesday, March 26, 2024 at 8:00 a.m. ET.
-
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
3/5/2024
Praxis Precision Medicines, Inc. provided a corporate update and reported financial results for the fourth quarter and full-year 2023.
-
Praxis Precision Medicines to Participate in TD Cowen’s 44th Annual Health Care Conference
3/1/2024
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) today announced that management will participate in the TD Cowen 44th Annual Health Care Conference, taking place in Boston from March 4 – 6, 2024.
-
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 02, 2024
2/2/2024
Praxis Precision Medicines, Inc. announced that on February 1, 2024, the Compensation Committee of Praxis’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 1,600 shares of its common stock and restricted stock unit awards covering an aggregate of 1,450 shares of its common stock to two new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan.
-
From ALS to depression to Huntington’s disease, many neuroscience-focused companies are anticipating key data over the next few months.
-
Praxis Precision Medicines, Inc. Announces Pricing of $150.0 Million Public Offering
1/11/2024
Praxis Precision Medicines , Inc. today announced the pricing of its underwritten public offering of 3,168,275 shares of its common stock at a public offering price per share of $35.50 and, in lieu of shares of common stock.
-
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
1/10/2024
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) today announced a proposed public offering of its common stock and, in lieu of common stock to certain investors, prefunded warrants to purchase shares of common stock.
-
Praxis Precision Medicines Provides Update on Advancing Clinical Stage Portfolio
1/8/2024
Praxis Precision Medicines, Inc. provided an update on its portfolio and planned key milestones in 2024.
-
Praxis Precision Medicines Announces Licensing and Collaboration Agreement with Tenacia Biotechnology for Ulixacaltamide in Greater China
1/5/2024
Praxis Precision Medicines today announced an exclusive collaboration and license agreement with Tenacia Biotechnology (Shanghai) Company, Ltd., a China-based clinical-stage biopharmaceutical company focused on CNS drug development and commercialization.
-
Praxis Precision Medicines to Showcase Largest Pipeline of Precision Epilepsy Programs and Breadth of Commitment to Epilepsy Treatments at Upcoming Meetings
11/28/2023
Praxis Precision Medicines, Inc. announced that it will deliver presentations on its epilepsy programs at the following upcoming meetings in Orlando, Florida.
-
Praxis Precision Medicines to Present at the Piper Sandler 35th Annual Healthcare Conference
11/21/2023
Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in a fireside discussion at the Piper Sandler Healthcare Conference on November 28, 2023 at 10:00am.
-
Praxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental Epilepsies
11/16/2023
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) today announced that the European Medical Agency (EMA) has awarded its Priority Medicines (PRIME) designation for elsunersen (PRAX-222) for the treatment of SCN2A Gain of Function (GoF) developmental and epileptic encephalopathy (DEE).
-
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2023 Financial Results
11/7/2023
Praxis Precision Medicines, Inc. provided a corporate update and reported financial results for the third quarter 2023.
-
Praxis Precision Medicines to Present at Truist Securities BioPharma Symposium
11/2/2023
Praxis Precision Medicines , Inc. today announced that management will participate in a panel discussion titled “CNS Companies Looking To Address High Unmet High Prevalence and High Value Diseases” at the Truist Securities BioPharma Symposium on November 8, 2023.